Weekly Digest – June 2025 Weekly Digest – June 2025 23 June 2025: DATROWAY approved in the U.S. as first TROP2 directed therapy for patients with previously treated advanced EGFR-mutated non-small cell lung cancer DATROWAY (datopotamab deruxtecan-dlnk) received accelerated approval in […]
Weekly Digest – June 2025 Weekly Digest – June 2025 24 June 2025: MediLink announces YL201 granted Breakthrough Therapy Designation by FDA The U.S. FDA has granted Breakthrough Therapy Designation to YL201, a B7H3-targeted ADC developed by MediLink Therapeutics, for […]
Weekly Digest – June 2025 Weekly Digest – June 2025 25 June 2025: Huadong Medicine’s FGFR2b target ADC innovative drug HDM2020 China IND was approved by the NMPA Zhongmei Huadong, a subsidiary of Huadong Pharmaceutical, received NMPA approval to initiate […]
Weekly Digest – June 2025 Weekly Digest – June 2025 24 June 2025: Dong-A ST files IND for Phase 1 clinical trial of ADC candidate for cancer Dong-A ST’s ADC subsidiary, Aptis, has submitted an IND application in South Korea […]
Weekly Digest – June 2025 Weekly Digest – June 2025 25 June 2025: Bio-Thera Solutions announce first patient dosed in Phase 3 clinical trial for BAT8006, an Antibody Drug Conjugate targeting folate receptor α for the treatment of platinum-resistant ovarian […]
Weekly Digest – June 2025 Weekly Digest – June 2025 25 June 2025: Corbus Pharmaceuticals announces first patient dosed with its Nectin-4 targeting ADC CRB-701 in combination with pembrolizumab Corbus Pharmaceuticals has dosed the first participant in the PD-1 combination […]
